Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown

Hims & Hers will cease offering its compounded semaglutide pill following a directive from the U.S. Food and Drug Administration. The telehealth company made the announcement on Saturday. The FDA said it would take action against the company for marketing the weight-loss drug at $49 per pill. Semaglutide is a medication used to manage weight. However, the FDA has not approved compounded versions of the pill. Therefore, Hims & Hers complied with the agency’s request to stop providing access to the product. The decision aligns with the FDA’s broader regulatory oversight to ensure drug safety and efficacy. The company did not provide additional comments on future plans regarding this product. Meanwhile, the FDA continues to monitor compounded medications offered via telehealth platforms.